FOUND - Ancillary Study to Smile Protocol NCT03654105
Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Jun 18, 2020
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Elegibility to annual LDCT screening
- • Absence of tumors for at least 5 years
- • Signed informed consent form meet inclusion criteria outlined in SMILE Protocol NCT03654105
- Exclusion Criteria:
- • Hypersensitivity to acetylsalicylic acid, salicylates or any of the excipients
- • Chronic treatment with acetylsalicylic acid, or other anti-clotting or anti-coagulant drugs
- • Treatment with methotrexate
- • Existing Mastocytosis
- • History of asthma induced by the administration of salicylates or substances to similar activity, particularly non-steroidal anti-inflammatory drugs
- • Gastroduodenal ulcer
- • Hemorrhagic diathesis
- • Severe chronic pathology
- • Serious psychiatric problems
- • Previous treatment with Cytisine
- • Abuse of alcohol or other substances
About Fondazione Irccs Istituto Nazionale Dei Tumori, Milano
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano is a leading cancer research and treatment institution in Italy, dedicated to advancing the understanding and management of oncological diseases. As a prominent clinical trial sponsor, the foundation focuses on innovative research aimed at developing new therapeutic strategies and improving patient outcomes. With a commitment to translational medicine, it collaborates with a network of national and international partners to facilitate cutting-edge clinical trials, enhance cancer care, and contribute to the global body of oncological knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Patients applied
Trial Officials
Ugo Pastorino, MD
Principal Investigator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials